Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.
Also called NCT05573477
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 255 participants
- Sponsor
- Autotelicbio
- Registry
-
NCT05573477
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05573477. Randomized; double masking; primary purpose treatment. Start 2022-11-16 (actual); primary completion 2025-08-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
- Condition
- Essential Hypertension
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- ATB-1011
- Intervention (Drug)
- ATB-1012
- Intervention (Drug)
- ATB-1013
- Intervention (Drug)
- ATB-1011 placebo
- Intervention (Drug)
- ATB-1012 placebo
- Intervention (Drug)
- ATB-1013 placebo
- Lead sponsor
- Autotelicbio
Record details
- Record id
cardio:ct-nct05573477- Content hash
babc69fbe7a51e1ee2bcf7f0fea46ea90a27f5c1b69bf8fbe89cfd5696fed590